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Background: Fish is the natural dietary source of vitamin D. Reports on the influence of 
purified omega-3 fatty acids on its uptake are scarce.
Objectives: We investigated the impact of a purified high-dose omega-3 compound 
compared to corn oil on 25-hydroxyvitamin D [25(OH)D] levels following an acute myo-
cardial infarction.
Methods: 228 patients were randomized 1:1 to receive a daily dose of either 4  g 
omega-3 (OMACOR®) or an equal dose of corn oil, administered double-blindly for 
12 months. Total omega-3 and omega-6 measurements were available in 40 randomly 
picked patients.
results: There was no significant intergroup difference in 25(OH)D changes at 12 months 
follow-up (p = 0.12), but there was a minor statistical significant intragroup increase in 
25(OH)D in both intervention arms (p < 0.001 for n-3 polyunsaturated fatty acids and 
p = 0.013 for corn oil, respectively). A positive correlation was noted between 25(OH)
D and omega-3 prior to inclusion; r = 0.418, p = 0.007, attenuated at 12 months by 
purified omega-3 intervention; r = 0.021, p = 0.93. No positive correlation was observed 
between omega-6 and 25(OH)D.
conclusion: Long-term treatment with a high dose of purified omega-3 as compared to 
corn oil did not improve serum concentrations of vitamin D.
clinical Trial registration: ClinicalTrials.gov, Identifier: NCT01422317.
Keywords: vitamin D, omega-3, acute myocardial infarction, 25-hydroxyvitamin D, omega-6
inTrODUcTiOn
Vitamin D can be synthesized in the human epidermis on exposure to ultraviolet light or it can be 
ingested mainly through consumption of oily fish (1). Thus, low levels of vitamin D can be caused 
by limited sun exposure and/or inadequate intake from the diet. Individual differences in vitamin D 
baseline concentration, absorption, and metabolism may also influence its level in humans.
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Previous studies indicate that different vehicles including n-3 
polyunsaturated fatty acids (PUFAs) may influence the bioavail-
ability of vitamin D (2). These studies have evaluated different 
patient populations, different vitamin D supplementations, and 
duration of intake.
We have previously shown that serum levels of 25- 
hydroxyvitamin D [25(OH)D] may predict total and cardiac 
mortality in chest pain patients with suspected acute coronary 
syndrome (3). Several other studies have demonstrated an inverse 
relationship between cardiovascular risk and levels of 25(OH)
D and omega-3 (4, 5). As 25(OH)D concentrations are gener-
ally found in the lower range of recommended levels (3), it is 
important to define all steps that may influence vitamin D intake, 
absorption, and deposition, in order to enforce recommendations 
as a preventive measure in relation to disease.
To determine whether a purified compound of omega-3 may 
positively influence the uptake of vitamin D, this would scientifi-
cally require a randomized study with purified omega-3 supple-
mentation as compared to a regular diet containing an equivalent 
amount of naturally occurring omega-3. Furthermore, such a study 
may not be acknowledged due to its open design. Another pos-
sibility would be to examine the influence of long-term treatment 
with a purified omega-3 compound on the association between 
omega-3 and vitamin D.
In 1990s, we performed a randomized, double-blind study 
including 300 patients with an acute myocardial infarction (MI), 
treated with a high dose of purified omega-3 as compared to corn 
oil (6). Serum levels of total omega-3 and omega-6 prior to and 
at completion of intervention were determined in a subset of 
patients (7).
It has previously been demonstrated that the uptake of a 
vitamin D supplement dissolved in fish oil may not differ as com-
pared to vitamin D administered as a multivitamin tablet, during 
an intervention period of 4  weeks (8). However, information 
related to long-term supplementation with omega-3 as compared 
to corn oil free of 25(OH)D with respect to vitamin D uptake 
from the diet has previously not been elucidated.
The primary aim of the present study was to evaluate whether 
a purified omega-3 compound (ethylester form) as compared 
to corn oil would increase the uptake of vitamin D provided in 
the diet.
Thus, in the present study we have retrospectively measured 
serum vitamin D levels as 25(OH)D in 228 patients hospitalized 
with a MI with available blood samples at baseline and during 
follow-up.
The second aim was to assess the correlation between 25(OH)
D and omega-3 and omega-6 fatty acids (FAs), respectively. This 
was performed in 19 and 21 randomly picked patients from the 
respective groups.
The present study was based on the hypothesis that a purified 
compound of omega-3 not containing vitamin D would have a 
limited impact on vitamin D concentrations.
MaTerials anD MeThODs
Participants in the present analysis belonged to the Omacor 
Following Acute Myocardial Infarction (OFAMI) study 
(ClinicalTrials.gov Identifier: NCT01422317), who were hos-
pitalized with a MI at Central Hospital in Rogaland, Stavanger, 
Norway from September 1995 until December 1996 and randomly 
assigned 1:1 in blocks of four to a daily dose of either 4 g highly 
concentrated omega-3 FA, containing 85% eicosapentaenoic acid 
and docosahexaenoic acid (OMACOR™, Pronova A/S, Oslo, 
Norway), or to corn oil (basically n-6 FAs), administered double 
blindly for at least 12 months. 4 mg of alpha-tocopherol was added 
to each capsule to protect against FA oxidation. Eligibility was 
based on several exclusion criteria, including liver dysfunction 
(6). A flow chart providing information related to recruitment 
and inclusion in the present study is presented in Figure 1. No 
significant amendments were made after trial commencement.
The diet contained a high intake of fish meals; two meals or 
less in the lower quartile and three meals or more in the upper 
quartile. The median intake consisted of three fish meals per 
week. Dietary habits remained essentially unchanged throughout 
the study period, whereas supplementary fish oil products were 
discontinued immediately following inclusion in the trial (6, 7).
Blood samples for the present analysis were available in 228 
OFAMI patients. 25(OH)D was measured at baseline, 6 weeks, 
and 12 months follow-up in these patients (114 patients received 
omega-3 FAs and 114 patients received corn oil, and number of 
fish meals was similar in both groups). In a substudy previously 
reported by Grundt et al. (9), total omega-3 and omega-6 FAs, 
respectively, were measured in serum phospholipids in samples 
from 60 randomly picked patients. These analyses were per-
formed during the study period at baseline and after 12 months of 
treatment. In this subpopulation, we investigated the association 
between FA and 25(OH)D levels.
Blood samples were drawn following admission, and serum for 
measurement of 25(OH)D was stored at −80°C for later analysis. 
25(OH)D analysis was performed at the Department of Medical 
Biochemistry, Stavanger University Hospital, by determination of 
the metabolites 25(OH)D3 and 25(OH)D2 in serum by liquid–
liquid extraction, derivatization with 4-phenyl-1,2,4-triazoline-
3,5-dione reagent (Sigma-Aldrich, St. Louis, MO, USA), and 
analysis by liquid chromatography coupled with tandem mass 
spectrometry detection, as previously described (3). The long-
term stability of 25(OH)D serum concentrations is maintained 
under these conditions (10).
Analyses of FAs in serum phospholipids were carried out at 
the University of Tromsø, Norway, as previously reported (11).
The study was approved by the Regional Board of Research 
Ethics and the Norwegian Health Authorities and conducted 
in accordance with the Declaration of Helsinki of 1971, as 
revised in 1983. Written informed consent was obtained from 
all patients. The details of the OFAMI study have been published 
previously (6).
statistical analysis
Changes in 25(OH)D from baseline to 6 weeks and 12 months 
follow-up, respectively, were calculated for each individual 
patient. The paired t-test was used to evaluate whether changes 
in parameter values from baseline to follow-up were significantly 
different from zero. The independent two-sample t-test was 
Paents asked to parcipate (n=701)
Included in the main study (n=300)
Samples available at inclusion, 
6 weeks and 12 months (n=228)
Samples not available due to deaths 
and incomplete sample set (N=72)
Received Omega-3 (n=150) Received Omega-6 (n=150)
Omega-6 group
Analysis of 25(OH)D (n=114)
Omega-3 group
Analysis of 25(OH)D (n=114)
FigUre 1 | Flow chart.
TaBle 1 | Patient characteristics at baseline according to treatment group.
characteristics (n) n-3 group 
(n = 114)
corn oil group 
(n = 114)
p-Value
Male sex 93 93 0.86
Current smoker 46 43 0.78
STEMI 47 51 0.69
Thrombolysis 46 50 0.69
Diabetes mellitus 14 10 0.52
Heart failure 8 5 0.57
Hypertension 25 26 0.88
EF < 30% 8 5 0.57
EF 30–50% 35 39 0.67
STEMI, ST elevation myocardial infarction; EF, ejection fraction.
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used to test for differences between the two treatment groups. 
Approximately normally distributed variables were given as mean 
and standard deviation (SD).
Spearman’s correlation coefficients were calculated between 
25(OH)D and total omega-3 and omega-6 FAs, respectively, and 
a two-tailed test from zero was applied.
The statistical analyses were performed using the statistical 
package SPSS version 19. All tests were two-sided with a signifi-
cance level of 5%. Highly significant differences were based on a 
two-tailed significance level of 1%.
The present study was based on the hypothesis that a purified 
compound of omega-3, not containing vitamin D, would have a 
limited impact on vitamin D concentrations. If a minor influence 
should be present, an increase below 5 nmol/L as compared to 
controls would be considered of less clinical relevance.
Given an SD of 12, and a 5% significance level, then 114 
patients in each group gives 99.3% power to detect a mean of 
5  nmol/L in the change from baseline within each group and 




A total of 228 available subjects from the OFAMI study (6) were 
included in the present analysis and followed up at 6  weeks 
and 12 months. In the present population, there were 186 men 
(61.6 ± 12.4 years) and 42 women (67.8 ± 11.0 years), equally 
divided between the two treatment groups. Patient characteristics 
at baseline according to treatment groups are presented in Table 1. 
There were no significant intergroup differences at baseline.
interventional study
Mean (±SD) 25(OH)D levels in the two groups at baseline, 
6  weeks, and 12  months on treatment are shown in Table  2. 
The increase in 25(OH)D was statistically significant in both 
treatment groups at 12 months (p < 0.001 for n-3 PUFAs and 
p  =  0.013 for corn oil, respectively). There was no significant 
TaBle 3 | Changes in biomarkers related to a subpopulation with known serum concentrations of fatty acids and 25(OH)D [mean (SD), n = 40].
n-3 group (n = 19) corn oil group (n = 21)
Baseline 12 months Baseline 12 months
Total n-3 PUFAs (μmol/L)2 285.41 (85.390) 466.016 (96.986)** 326.352 (131.588) 367.933 (155.642)
Total n-6 PUFAs (μmol/L)1 1,185.690 (312.469) 1,052.963 (177.628) 1,283.400 (281.854) 1,348.552 (231.660)
Total saturated FAs (μmol/L) 2,020.584 (440.313) 2,000.258 (229.395) 2,153.091 (393.898) 2,205.952 (305.543)
Ratio n-3/n-62 0.2514 (0.0887) 0.458 (0.132)** 0.2631 (0.1179) 0.282 (0.1323)
Cholesterol (mmol/L) 5.47 (0.98) 5.24 (0.79) 5.93 (1.13) 5.76 (0.91)
HDL-cholesterol (mmol/L) 0.96 (0.18) 1.22 (0.26)** 1.17 (0.35) 1.24 (0.35)
Triglycerides (mmol/L) 1.78 (1.09) 1.35 (0.51) 1.43 (0.63) 1.73 (0.78)
Vitamin D [25(OH)D] (nmol/L) 54.275 (16.104) 57.409 (20.392) 58.575 (21.734) 59.106 (22.605)
Intragroup difference from baseline to 12 months; **p < 0.001.
No difference between groups at baseline, except for HDL cholesterol, p = 0.029.
Significance of difference in change from baseline between groups: 1p = 0.05, 2p < 0.001.
25(OH)D, 25-hydroxyvitamin D; PUFA, polyunsaturated fatty acid.
TaBle 2 | 25(OH)D nmol/L levels at baseline, after 6 weeks, and after 
12 months supplementation with high dose of n-3 PUFAs (n = 114) as compared 
to corn oil (n = 114).
25(Oh)D nmol/l mean (±sD)
Baseline 6 weeks 12 months
n-3 PUFAs (n = 114) 51.25 ± 15.15 52.66 ± 14.57 56.22 ± 17.77**
Corn oil (n = 114) 54.82 ± 17.78 55.64 ± 17.82 57.43 ± 19.16*
No significant difference between groups at baseline, p = 0.10 (independent t-test).
**p < 0.001 as compared to baseline (paired t-test).
*p = 0.013 as compared to baseline (paired t-test).
No significant difference between intergroup changes after 6 weeks intervention 
(p = 0.61) or after 12 months intervention (p = 0.12).
25(OH)D, 25-hydroxyvitamin D; PUFA, polyunsaturated fatty acid.
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intergroup difference between changes in 25(OH)D concen-
trations after 6  weeks (p  =  0.61) and 12  months intervention 
(p = 0.12).
The FA profiles did not differ between the treatment groups at 
baseline. In the group receiving n-3 PUFAs, the total amount of 
n-3 FAs increased significantly as compared to the group receiv-
ing n-6 PUFAs (p = 0.02), as shown in Table 3.
correlation study
The correlation between 25(OH)D and omega-3 FAs prior to 
inclusion was found to be statistically significant (r  =  0.418, 
p  =  0.007), whereas no statistically significant correlation was 
found between 25(OH)D and omega-6 FAs (r = −0.073, p = 0.66). 
At 12  months intervention with n-3 PUFAs the correlation 
between 25(OH)D and omega-3 and omega-6, respectively, was 
no longer significant (r = 0.021, p = 0.93 and r = 0.163, p = 0.51, 
respectively). At 12  months intervention with corn oil, the 
omega-6 was negatively correlated with 25(OH)D (r = −0.469, 
p = 0.032). These correlation results are presented in Table 4.
DiscUssiOn
In the present population consisting of a total of 228 subjects 
with an acute MI, there was a minor, but statistically significant 
increase in levels of 25(OH)D at 12  months in both treatment 
groups. However, there was no significant difference in vitamin D 
concentrations in the omega-3 group as compared to the corn oil 
group of patients (p = 0.12). Whether the improvement in both 
groups is a consequence of intervention or whether it reflects 
post-MI dietary changes cannot be determined. Although puri-
fied compounds of omega-3 do not contain vitamin D, treatment 
with such compounds might enhance vitamin D absorption 
from other food sources and/or might upregulate vitamin D 
receptors. In the present patient material, vitamin D levels were 
found to be suboptimal as compared to recommended concentra-
tions above 75  nmol/L, as shown in Table  2. As the values are 
fairly low, we might expect an increased influence of omega-3 
on the uptake of vitamin D from the diet. We found a statisti-
cally non-significant intergroup difference in vitamin D levels of 
2.4 nmol/L. Even if this difference had been statistically different, 
its clinical relevance would be negligible according to our hypoth-
esis. Furthermore, although the omega-3 levels in our patients 
prior to intervention were high as compared to other populations 
(6), vitamin D levels were low, lending support to our assumption.
The background diet of the present population was rich in 
omega-3, allowing us to investigate the relation between dietary 
omega-3 and vitamin D at baseline. Prior to intervention we 
observed a statistically significant positive correlation between 
omega-3 and 25(OH)D. However, after 12 months intervention 
with a high dose of purified omega-3, the positive correlation 
between omega-3 and 25(OH)D was lost. Dietary omega-6 was 
not found to correlate with 25(OH)D and intervention with corn 
oil resulted in a negative correlation.
These results may support previous findings related to a 
healthy population, in which 25(OH)D was positively associ-
ated with total daily monounsaturated FAs intake and inversely 
associated with total PUFAs intake, usually consisting of a high 
proportion of n-6 as compared to n-3 FAs (12). Moreover, Itariu 
et al. (13) employed a comparable dose of OMACOR™ to that of 
the present study for 8 weeks and found that purified n-3 PUFAs 
did not affect vitamin D status, which is largely in agreement with 
our findings.
Overall, these results would suggest that the increase in 
vitamin D in our two intervention groups may rather be related 
to a recovery situation, including dietary and lifestyle changes 
TaBle 4 | Spearman correlation coefficients between 25(OH)D and fatty acids at 
baseline and after 12 months intervention with PUFAs or CO.










r p-Value r p-Value r p-Value
Total saturated FAs 0.057 0.73 0.205 0.40 −0.077 0.74
Total n-3 PUFAs 0.418 0.01 0.021 0.93 0.482 0.03
Total n-6 PUFAs −0.073 0.66 0.163 0.51 −0.469 0.03
25(OH)D, 25-hydroxyvitamin D; FAs, fatty acids; CO, corn oil; PUFAs, polyunsaturated 
fatty acids.
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following an acute MI and not to the intervention per  se. 
Furthermore, our correlation findings indicate that omega-3 may 
not act alone as a vehicle for vitamin D absorption, as demon-
strated by the attenuation of the correlation between omega-3 
and vitamin D following intervention with a purified compound 
of omega-3.
Holvik et al. (8) have shown that the uptake of vitamin D did not 
depend on whether vitamin D was given as a multivitamin tablet or 
as a fish oil capsule, both containing the same amount of vitamin D. 
Essentially, similar results were obtained by Tang pricha et al. (14), 
who studied three different vehicles with vitamin D fortification. 
This would also support our findings that vitamin D is indepen-
dently associated with omega-3 FAs in diets containing fish.
No negative correlation was observed in the omega-3 inter-
vention group, whereas the positive correlation at baseline was 
inversed by 12 months of corn oil intervention. This would imply 
that the latter compound may negatively influence the relationship 
between vitamin D and omega-3. These results are in agreement 
with those of Olsen et al. (15), who investigated the associations 
of plasma vitamin D, marine PUFAs, and PUFA ratios in women 
from the Norwegian Women and Cancer Post-Genome Cohort. 
In that study, vitamin D levels were found to be weakly associated 
with PUFA ratios, mainly containing omega-6 FAs, but signifi-
cantly associated with marine FAs.
Although vitamin D is positively correlated with omega-3 
in the background diet, attenuation of the vitamin D levels by 
purified n-3 PUFAs may indirectly suggest the coexistence of 
additional vehicles for vitamin D absorption in a marine diet. 
This assumption is supported by results of dietary intervention 
studies such as DART 1 (16), that of Kromhout et al. (17), and 
JPHC (18), in which a diet rich in natural fish oils was found to be 
beneficial in relation to clinical outcome, whereas other studies, 
such as ORIGIN (19), using purified omega-3 oils have shown 
neutral results on outcome.
The GISSI Prevention trial (20) and the GISSI HF study (21) 
have demonstrated clinical benefits of OMACOR™ 1 g per day, 
whereas ORIGIN (19) did not, and we are still awaiting the results 
of the ASCEND study (22). Also, other large intervention studies, 
such as JELIS (23), claim a benefit of purified omega-3, but results 
of meta-analyses (24, 25) still remain controversial with respect 
to the clinical benefit of purified omega-3 compounds. In dietary 
studies, claiming a beneficial effect of omega-3, vitamin D may 
contribute to the improved prognosis.
The present study was designed to evaluate the association 
between vitamin D and different PUFAs, administered as either 
omega-3 or corn oil, and not to investigate the clinical perfor-
mance of these PUFAs. Our findings suggest that vitamin D may 
be an independent player of importance in an omega-3 rich diet.
limitations
Our study was performed retrospectively. The analyses of 
vitamin D and FAs in serum phospholipids were performed 
without knowledge of treatment regimen.
The blood samples were stored for more than 10 years before 
the measurement of vitamin D. However, it has been shown that 
vitamin D is stable and will not be significantly affected by long-
term storage (10).
Our correlation study suggests an attenuating effect of both 
purified PUFA compounds on vitamin D, which is indirect 
evidence and should be considered with caution.
In conclusion, high doses of purified omega-3 FAs have a low 
impact on the levels of vitamin D and weaken the correlation 
between omega-3 and vitamin D.
eThics sTaTeMenT
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